MedTrace Logo

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00817778 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-11-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin

Conditions

Interventions

DRUG

AZD1656

Subjects will be treated with tolerable dose twice daily for another 24 days.

DRUG

Placebo

Subjects will be treated with tolerable dose twice daily for another 24 days.

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD, Prof · AstraZeneca R&D Mölndal

  • Emanuel P DeNoia, M.D · Healthcare Discoveries LLC Icon Development Solutions

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817778 on ClinicalTrials.gov